$1.100
+0.010 (+0.92%)收盤時
- High
- 1.110
- Open
- 1.090
- VWAP
- 1.10
- Vol
- 6.74K
- Mkt Cap
- 39.68M
- Low
- 1.085
- Amount
- 7.40K
- EV/EBITDA, TTM
- -0.69
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
估值指標
事件時間軸
資訊
9.006-03NewsfilterIN8bio Publishes Review on γδ T Cell Therapies
- 9.006-01Newsfilter
IN8bio Updates Clinical Data on DeltEx DRI Therapy
9.505-08seekingalphaIN8bio Reports Q1 Loss but Promising Data Ahead
- 9.505-07Newsfilter
IN8bio Advances γδ T Cell Engager Platform with Promising Data
- 9.503-12seekingalpha
IN8bio Reports FY Loss and Launches $40.2M Private Placement
INAB FAQ — answered by Alphio AI
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。